Time-dependent efficacy of combination of silver-containing hydroxyapatite coating and vancomycin on methicillin-resistant Staphylococcus aureus biofilm formation in vitro
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-0500
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Time-dependent efficacy of combination of silver-containing hydroxyapatite coating and vancomycin on methicillin-resistant Staphylococcus aureus biofilm formation in vitro ; volume:14 ; number:1 ; day:2 ; month:3 ; year:2021 ; pages:1-5 ; date:12.2021
BMC Research Notes / Biomed Central; 14, Heft 1 (2.3.2021), 1-5, 12.2021
- Urheber
-
Hashimoto, Akira
Miyamoto, Hiroshi
Kii, Sakumo
Kobatake, Tomoki
Shobuike, Takeo
Noda, Iwao
Sonohata, Motoki
Mawatari, Masaaki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13104-021-05499-7
- URN
-
urn:nbn:de:101:1-2021041621064336889737
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hashimoto, Akira
- Miyamoto, Hiroshi
- Kii, Sakumo
- Kobatake, Tomoki
- Shobuike, Takeo
- Noda, Iwao
- Sonohata, Motoki
- Mawatari, Masaaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Vancomycin‐Loaded Microneedle Arrays against Methicillin‐Resistant Staphylococcus Aureus Skin Infections
Vancomycin creep and daptomycin minimum inhibitory concentration in methicillin-resistant staphylococcus aureus
Treatment of Methicillin-resistant Staphylococcus aureus experimental Osteomyelitis with bone-targeted Vancomycin
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
P067: Economic burden of methicillin-resistant Staphylococcus aureus, Clostridium difficile, and vancomycin-resistant enterococci in hospitals
Recurrent Challenges for Clinicians: Emergence of Methicillin-resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options
Vancomycin heteroresistance among methicillin-resistant clinical isolates S. haemolyticus, S. hominis, S. simulans, and S. warneri
In vitro antibacterial effects of Tanreqing injection combined with vancomycin or linezolid against methicillin-resistant Staphylococcus aureus
USA300 Methicillin-resistant Staphylococcus aureus in Cuba
Confounding by indication affects antimicrobial risk factors for methicillin-resistant Staphylococcus aureus but not vancomycin-resistant enterococci acquisition
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Vancomycin‐Loaded Microneedle Arrays against Methicillin‐Resistant Staphylococcus Aureus Skin Infections
Vancomycin creep and daptomycin minimum inhibitory concentration in methicillin-resistant staphylococcus aureus
Treatment of Methicillin-resistant Staphylococcus aureus experimental Osteomyelitis with bone-targeted Vancomycin
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
P067: Economic burden of methicillin-resistant Staphylococcus aureus, Clostridium difficile, and vancomycin-resistant enterococci in hospitals
Recurrent Challenges for Clinicians: Emergence of Methicillin-resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options
Vancomycin heteroresistance among methicillin-resistant clinical isolates S. haemolyticus, S. hominis, S. simulans, and S. warneri
In vitro antibacterial effects of Tanreqing injection combined with vancomycin or linezolid against methicillin-resistant Staphylococcus aureus
USA300 Methicillin-resistant Staphylococcus aureus in Cuba
Confounding by indication affects antimicrobial risk factors for methicillin-resistant Staphylococcus aureus but not vancomycin-resistant enterococci acquisition
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Vancomycin‐Loaded Microneedle Arrays against Methicillin‐Resistant Staphylococcus Aureus Skin Infections
Vancomycin creep and daptomycin minimum inhibitory concentration in methicillin-resistant staphylococcus aureus
Treatment of Methicillin-resistant Staphylococcus aureus experimental Osteomyelitis with bone-targeted Vancomycin
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
P067: Economic burden of methicillin-resistant Staphylococcus aureus, Clostridium difficile, and vancomycin-resistant enterococci in hospitals
Recurrent Challenges for Clinicians: Emergence of Methicillin-resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options
Vancomycin heteroresistance among methicillin-resistant clinical isolates S. haemolyticus, S. hominis, S. simulans, and S. warneri
In vitro antibacterial effects of Tanreqing injection combined with vancomycin or linezolid against methicillin-resistant Staphylococcus aureus
USA300 Methicillin-resistant Staphylococcus aureus in Cuba
Confounding by indication affects antimicrobial risk factors for methicillin-resistant Staphylococcus aureus but not vancomycin-resistant enterococci acquisition